Elevance Health, Inc. · Healthcare · Healthcare Plans
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$319.99
−$3.07 (−0.95%) 4:00 PM ET
After hours$319.02
−$0.97 (−0.30%) 6:13 PM ET
Prev closePrevC$323.05
OpenOpen$326.03
Day highHigh$326.03
Day lowLow$311.27
VolumeVol3,971,646
Avg volAvgVol1,864,807
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$70.63B
P/E ratio
12.70
FY Revenue
$199.13B
EPS
25.19
Gross Margin
25.56%
Sector
Healthcare
AI report sections
MIXED
ELV
Elevance Health, Inc.
No AI report section text found yet for this symbol.
AI summarized at 6:52 PM ET, 2025-04-04
Volume vs average
Intraday (cumulative)
+290% (Above avg)
Vol/Avg: 3.90×
RSI
38.31(Weak)
Weak (30–40)
0255075100
MACD momentum
Intraday
-0.02 (Weak)
MACD: -0.67 Signal: -0.64
Short-Term
-1.00 (Weak)
MACD: -5.53 Signal: -4.53
Long-Term
-1.45 (Weak)
MACD: -4.62 Signal: -3.18
Intraday trend score
47.50
LOW31.50HIGH56.00
Latest news
ELV•12 articles•Positive: 1Neutral: 7Negative: 4
NegativeInvesting.com• Timothy Fries
Humana Stock Down as Medicare Rate Proposal Hits Insurers
Humana shares plummeted 13.49% in premarket trading following the Trump administration's proposal for nearly flat Medicare Advantage payment rates for 2027, with only a 0.09% net average payment increase versus Wall Street expectations of 4-6%. The broader health insurance sector also suffered significant losses, with CVS Health, UnitedHealth Group, and Elevance Health all declining sharply.
Stock dropped 6.90% in after-hours trading as a health insurance provider impacted by the low Medicare Advantage payment rate increase and proposed elimination of certain billing practices.
NegativeBenzinga• Vandana Singh
Medicare Shock Sends UnitedHealth, Humana And CVS Tumbling
The Centers for Medicare & Medicaid Services (CMS) proposed a 2027 Medicare Advantage payment increase of only 0.09%, significantly below Wall Street's expectations of 4-6%. This modest growth announcement triggered sharp declines in major health insurer stocks, with UnitedHealth, Humana, and CVS Health leading the losses. The CMS emphasized program sustainability and payment accuracy through updated risk adjustment models.
Stock dropped 7.14% due to exposure to Medicare Advantage plans facing reduced payment growth in 2027.
NeutralBenzinga• Vandana Singh
UnitedHealth CEO Says Hospitals, Drug Prices Drive US Health Care Costs, Pledges ACA Rebates
UnitedHealth Group CEO Stephen Hemsley testified before House panels that rising hospital prices, consolidation, and prescription drug costs—not insurers—are the primary drivers of U.S. health care spending. He pledged to voluntarily eliminate and rebate profits on ACA exchange coverage this year and urged policy reforms including site-neutral payments and patent reform. UnitedHealth also announced a pilot program to accelerate Medicare Advantage payments for rural hospitals.
Mentioned as appearing before House panels alongside other insurers but no specific company actions or statements reported in the article.
PositiveInvesting.com• Damian Nowiszewski
3 Beaten-Down Stocks Ready to Kick Off 2026 on the Front Foot
As US stocks start 2026 with positive momentum and the S&P 500 near record highs above 6,900 points, three previously underperforming stocks show signs of recovery. Flowco Holdings is forming a rounding pattern with potential upside to $26, Elevance Health is testing key resistance at $360 with a path to $450, and Matador Resources shows strong fundamentals with a 50% fair value gap and potential recovery above $53.
Rebounded from long-term lows and testing key resistance at $360. Potential for further gains toward $450 if resistance breaks, closing 11% of gap to fair value estimate.
NeutralThe Motley Fool• Jonathan Ponciano
Why a 63% Vertex Selloff Didn’t Scare Off a New $13 Million Investor
Hyperion Capital Advisors acquired 540,000 shares of Vertex (VERX) worth $13.39 million in Q3, making it the fund's third-largest holding. Despite a 63% stock decline over the past year, the investment signals confidence in Vertex's underlying business fundamentals, including 12.7% revenue growth, 30% cloud revenue growth, and strong cash generation with a $150 million share buyback authorization.
Listed as second-largest holding in Hyperion's portfolio (8.9% of AUM). Mentioned as part of fund's preference for durable cash-generating businesses, but no specific analysis provided.
NeutralBenzinga• Vandana Singh
White House Set To Unveil Framework To Extend Obamacare Subsidies
The White House is preparing to introduce a healthcare framework to extend Affordable Care Act subsidies, proposing a two-year extension with updated eligibility limits and measures to control premium increases affecting approximately 22 million Americans.
With market volatility increasing, the article highlights three dividend-paying stocks that reported strong Q3 earnings: Travelers Companies, Elevance Health, and Church & Dwight. These stocks offer potential stability and consistent income amid uncertain market conditions.
Beat earnings estimates with 12% YOY operating revenue growth, but facing margin pressures and uncertain stock direction
NeutralBenzinga• Vandana Singh
Centene And Oscar Health Stocks Sink After Molina Warning
Molina Healthcare reported disappointing annual guidance, causing stocks of healthcare insurance providers Centene and Oscar Health to decline. The company expects higher medical cost trends across segments, particularly in the Marketplace, impacting investor confidence.
Reported mixed results with earnings beating estimates but facing Medicare cost pressures and Medicaid attrition
NeutralInvesting.com• Timothy Fries
Elevance Health: Solid Q3 Results Support Confident Full-Year Guidance
Elevance Health reported Q3 2025 operating revenue of $50.1 billion, a 12% increase from 2024, with diluted EPS of $5.32. The company maintained full-year guidance despite challenges in Medicaid membership and increased medical costs.
Mixed financial performance with revenue growth but decreased operating gains, offset by confident full-year guidance and strategic investments in technology and workforce
NeutralBenzinga• Vandana Singh
Humana Loses Court Battle Over Medicare Advantage Ratings, Billions In Payments At Risk
Humana lost a legal challenge against federal government cuts to its Medicare Advantage bonus payments, with a Texas judge upholding the downgrade of its star ratings. This ruling could potentially impact billions in revenue for the company.
Mentioned as having previously won similar legal challenges, with no direct negative impact in this article
NegativeGlobeNewswire Inc.• Joshua H. Grabar
Important Notice to Long-Term Shareholders of Elevance Health, Inc. (NYSE: ELV); Humana Inc. (NYSE: HUM); Maison Solutions Inc. (NASDAQ: MSS); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf
Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for several companies, including Elevance Health, Humana, Maison Solutions, and Vestis Corp, alleging misleading financial statements and undisclosed material risks.
Allegations of misleading statements about cost monitoring and premium rate negotiations, particularly regarding Medicaid patient costs
NegativeGlobeNewswire Inc.• Grabar Law Office
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Elevance Health Inc. (NYSE: ELV); Fluor Corporation (NYSE: FLR); and Fly-E Group, Inc. (NASDAQ: FLYE): Grabar Law Office is Investigating Claims on Your Behalf
Law firm investigating potential securities fraud and fiduciary breaches for four publicly traded companies, alleging misleading statements and undisclosed material facts that harmed shareholders.
Allegations of misrepresenting cost trends and patient risk profiles in Medicaid redetermination process
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal